Molecular Partners (MOLN) Expected to Announce Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) is anticipated to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Molecular Partners to announce earnings of ($0.46) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 AM ET.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Tuesday, August 25th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. On average, analysts expect Molecular Partners to post ($1.28) EPS for the current fiscal year and ($0.36) EPS for the next fiscal year.

Molecular Partners Stock Performance

MOLN stock opened at $3.70 on Thursday. The firm has a market capitalization of $149.39 million, a price-to-earnings ratio of -2.16 and a beta of 1.11. The company’s 50 day moving average price is $4.11 and its 200 day moving average price is $4.07. Molecular Partners has a fifty-two week low of $3.52 and a fifty-two week high of $5.36.

Analyst Ratings Changes

Several brokerages have weighed in on MOLN. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Molecular Partners currently has an average rating of “Hold” and an average target price of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines.

Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets.